5-Amino-1MQ — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Small-molecule NNMT inhibitor
Reported half-life: Short; published rodent designs use daily administration
Routes used in the literature: Oral and intraperitoneal in mouse studies
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Diet-induced obesity mouse models

Reported quantity: 5–20 mg/kg, most commonly 10 mg/kg
Frequency: Once daily
Study duration: 11 days in the original study; up to 8 weeks in later work

Adipocyte size and body-fat percentage were the reported endpoints.

Enzyme inhibition assays

Reported quantity: IC50 in the low micromolar range against NNMT
Frequency: Single exposure
Study duration: Assay timescale

Selectivity against related methyltransferases is the key question in these assays.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

5-Amino-1MQ · 10 mg Vial

5-Amino-1MQ is dosed at 2.5 mg–5 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 5 mg/mL. This information is for research and educational use only.

Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration.
Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Subcutaneous Protocol (2 mL = 5 mg/mL)

Phase	Daily Dose (mg)	Units (per injection) (mL)
Days 1–2 (Tolerance)	2.5 mg (2500 mcg)	50 units (0.50 mL)
Days 3+ (Standard)	5 mg (5000 mcg)	100 units (1.00 mL)
Alternative BID	2.5 mg twice daily	50 units (0.50 mL) × 2

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size 5-Amino-1MQ is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

5-Amino-1MQ · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	2.50 mg =	5 mg =
5 mg	1.67 mg/ml	17 mcg	150 units	300 units

Unit columns use the range reported for this compound (2.50 mg–5 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

Not a peptide — usually supplied as capsules or a powder for oral use rather than a lyophilised vial.

Open the reconstitution calculator

How to read these figures

NNMT sits in NAD+ metabolism, so effects are systemic rather than tissue-specific.
No human pharmacokinetic data has been published — oral bioavailability in humans is unknown.
Marketed claims run far ahead of an 11-day mouse study.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Neelakantan H, et al. · Biochem Pharmacol · 2017 · PMC5826726
Diet-induced obese mice were treated with the NNMT inhibitor 5-amino-1-methylquinolinium (5-amino-1MQ) daily, which reduced adiposity and reversed high-fat-diet-induced obesity.
View the record
[2]
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction
Babula JJ, Bui D, Stevenson HL, Watowich SJ, et al. · Diabetes Obes Metab · 2024 · DOI 10.1111/dom.15879
Administration of an NNMT inhibitor related to 5-amino-1MQ to diet-induced obese mice improved metabolic dysfunction over a defined dosing period.
View the record
[3]
Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice
Kraus D, et al. (reduced calorie diet + NNMTi study) · Sci Rep · 2021 · DOI 10.1038/s41598-021-03670-5
Diet-induced obese mice were dosed with an NNMT inhibitor (5-amino-1-methylquinolinium) combined with a low-fat diet, producing rapid normalization of adiposity and body weight.
View the record

Search the databases yourself

Read the 5-Amino-1MQ research brief

Other performance compounds

ACE-031Soluble activin receptor type IIB fused to an IgG1 Fc domain (myostatin trap)DermorphinHeptapeptide opioid agonist originally isolated from Phyllomedusa frog skin SS-31Mitochondria-targeted tetrapeptide

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.